Passing the baton: Kiran Mazumdar-Shaw (left), executive chairperson, Biocon, and niece Claire Mazumdar, chief executive ...

Bengaluru-based Biocon said that its Q4 profit stood at ₹198.6. The profit was hit by an exceptional item outgo of ₹80.4 crore on various heads, including the impact of the new labour code.

Shaw, founder and chairperson of Biocon , said on Tuesday that she plans a phased leadership transition over the next ​five years, with her niece Claire Mazumdar expected to eventually take over ‌as ...

Biocon shares jump 8% post Q4 results. Is the Street happy? Biocon's shares surged by 8% on Tuesday due to strong Q4 earnings growth. Net profit grew by 31% to INR 313 crore with ...

The company’s market capitalisation stood at ₹59,673 crore, with over 2 lakh shares changing hands over the counter, compared to the two-week average of 0.77 lakh shares. Sign up for Fortune India's ...

At the time of filing this report, the stock of the Bangalore-based company was trading at Rs 240.10 apiece on the BSE, down ...

Biocon has resolved FDA concerns about a biologics plant in India, a step that sets it and partner Mylan up to potentially win the first U.S. approval of a biosimilar of Roche’s blockbuster cancer ...

Track Biocon share price today on NSE/BSE with real-time updates. Check stock performance, fundamentals, market cap, shareholding, financial reports, annual & quarterly results, and profit & loss ...

Unveiled by Biocon Chairperson Kiran Mazumdar-Shaw, the programme is part of the Station Access and Mobility Program (STAMP), ...

Viatris Inc. , the company formed by the merger of Mylan and Pfizer Inc. unit Upjohn in 2020, said Monday it has reached an agreement to combine its biosimilars portfolio with Biocon Biologics Ltd.

Biocon Biologics has been positioning itself to become a global player in biosimilar drugs. Viatris, a longtime partner to Biocon, is charting a course for its future that does not include biosimilars ...

Biocon Biologics Limited on Thursday announced the successful pricing of Biocon Biologics’ debut USD 800 million (INR 66,763 million) senior secured Notes due 2029 at a coupon of 6.67 percent.